Sumitomo Pharma agrees to acquire Myovant Sciences
Sumitomo Pharma, and its subsidiary Sumitovant Biopharma, have agreed to acquire the remaining stake in Myovant Sciences at an improved price of $27 per share in cash. Earlier
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XSumitomo Pharma, and its subsidiary Sumitovant Biopharma, have agreed to acquire the remaining stake in Myovant Sciences at an improved price of $27 per share in cash. Earlier
AbbVie has signed an agreement to acquire UK-based biotechnology company DJS Antibodies (DJS) for a total consideration of $255m. DJS is engaged in the development and commercialisation of
Jazz Pharmaceuticals has signed a licensing deal with a subsidiary of Canadian biotechnology company Zymeworks for the latter’s cancer drug zanidatamab. Under the terms of the deal, Jazz
US-based pharmaceutical company Lilly has signed a definitive agreement to acquire precision genetic medicine company Akouos for about $487m. Under the terms of the agreement, Lilly will acquire
Gilead Sciences has signed an exclusive option and collaboration agreement with MacroGenics to develop bispecific antibodies using the latter’s DART platform. Under the terms of the agreement, Gilead
US-based precision oncology platform company Tavros Therapeutics has teamed up with Vividion Therapeutics, a subsidiary of German pharmaceutical company Bayer. The collaboration aims to discover four oncology targets,
US-based DNA sequencing company Illumina and British biopharmaceutical company AstraZeneca have announced a strategic research collaboration focused on drug target discovery. Under the partnership, the two companies will
scPharmaceuticals, a US-based company focused on infused therapies, has secured the US Food and Drug Administration (FDA) approval for Furoscix to treat a type of heart failure. Furoscix
The US Food and Drug Administration (FDA) has expanded approval for GlaxoSmithKline (GSK)’s Boostrix (Tdap) vaccine for administration during the third trimester of pregnancy. Boostrix was initially approved
German biotech company BioNTech has entered a strategic collaboration with Australia’s State of Victoria, to research and develop potential mRNA-based vaccines and therapies. Under the partnership, both parties